Molecular distinctions among ERBB2-overexpressing breast cancers
نویسندگان
چکیده
منابع مشابه
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
In breast cancer, overexpression of ErbB2 or aberrant regulation of survivin, a member of the inhibitor of apoptosis family, is associated with resistance to chemo/hormone therapy and predicts for a poor clinical outcome. A functional link between the two predictive factors has not been previously shown. Here, using genetic and pharmacologic approaches to block ErbB2 signaling, we show that Erb...
متن کاملNeu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
Neu differentiation factor (NDF), a member of the epidermal growth factor (EGF)-related peptide family, activates ErbB2 via heterodimerization with the NDF receptors ErbB3 and ErbB4. In a similar fashion, EGF receptor (EGFR) agonists induce heterodimers of EGFR and ErbB2. In this paper, we show that the ErbB2-overexpressing breast tumor cells SKBR3, AU565, and MDA-MB453 are growth inhibited by ...
متن کاملLapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Trastuzumab antitumor activity in ErbB2-overexpressing breast cancers seems to be dependent upon the presence of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), a phosphatase that dampens phosphatidylinositol 3-kinase-Akt signaling. Consequently, PTEN deficiency, which occurs in 50% of breast cancers, predicts for resistance to trastuzumab monotherapy. Here, we show that lapat...
متن کاملErk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.
The four receptor tyrosine kinases of the ErbB family play essential roles in several physiological processes and have also been implicated in tumor generation and/or progression. Activation of ErbB1/EGFR is mainly triggered by epidermal growth factor (EGF) and other related ligands, while activation of ErbB2, ErbB3, and ErbB4 receptors occurs by binding to another set of EGF-like ligands terme...
متن کاملClinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer.
mic ATP-binding site of the receptor TK, lapatinib blocks receptor phosphorylation and prevents subsequent downstream signaling. This is in contrast to trastuzumab which acts primarily by stimulating antibody-dependent cellular cytotoxicity (ADCC) [8, 9]. The rationale for the development of a dual inhibitor is threefold: Firstly, the combined blockage of two receptors involved in tumor prolife...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Breast Cancer Research
سال: 2005
ISSN: 1465-542X
DOI: 10.1186/bcr1065